✦ LIBER ✦

PMH75 PREDICTORS AND COSTS OF MDD TREATMENT WITH DULOXETINE COMPARED WITH VENLAFAXINE EXTENDED RELEASE

✍ Scribed by R Swindle; W Ye; RL Robinson; Y Zhao

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMH45 COST EFFECTIVENESS OF DULOXETINE C

✍ M Van Baardewijk; PM Vis; T Einarson 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Acute and Continuation Treatment Adequac

✍ Dr. Kristina S. Yu-Isenberg; Ms. Christina L. Fontes; Dr. George J. Wan; Ms. Eri 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB

PMH19 COMPARATIVE ANALYSIS OF THE EFFICA

✍ J Walczak; S Matysiak; M Rowinska 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Cost-Effectiveness Evaluation in Sweden

✍ Göran Nordström; Natalya Danchenko; Nicolas Despiegel; Florence Marteau 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 810 KB

P-471 - Evaluation of potential predicto

✍ M. Bauer; M. Thase; S. Liu; W. Earley; H. Eriksson 📂 Article 📅 2012 🏛 Elsevier Science 🌐 French ⚖ 93 KB

EPA-0264 – A Cost-utilty analysis of ven

✍ Graham, C.; Narula, H.; Liu, L.Z.; Keohane, D.; Di Virgilio, R. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 French ⚖ 64 KB